FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2101178715> ?p ?o ?g. }

• W2101178715 endingPage "67" @default.
• W2101178715 startingPage "67" @default.
• W2101178715 abstract "Hyperemesis gravidarum is a disabling disease of nausea, vomiting, and undernutrition in early pregnancy for which there are no effective outpatient therapies. Poor weight gain in hyperemesis gravidarum is associated with several adverse fetal outcomes including preterm delivery, low birthweight, small for gestational age, low 5-minute Apgar scores, and neurodevelopmental delay. Gabapentin is most commonly used clinically for treating neuropathic pain but also substantially reduces chemotherapy-induced and postoperative nausea and vomiting. Pregnancy registry data have shown maternal first-trimester gabapentin monotherapy to be associated with a 1.2% rate of major congenital malformations among 659 infants, which compares favorably with the 1.6% to 2.2% major congenital malformation rate in the general population. Open-label gabapentin treatment in hyperemesis gravidarum was associated with reduced nausea and vomiting and improved oral nutrition.This study aimed to determine whether gabapentin is more effective than standard-of-care therapy for treating hyperemesis gravidarum.A double-blind, randomized, multicenter trial was conducted among patients with medically refractory hyperemesis gravidarum requiring intravenous hydration. Patients were randomized (1:1) to either oral gabapentin (1800–2400 mg/d) or an active comparator of either oral ondansetron (24–32 mg/d) or oral metoclopramide (45–60 mg/d) for 7 days. Differences in Motherisk–pregnancy-unique quantification of nausea and emesis total scores between treatment groups averaged over days 5 to 7, using intention-to-treat principle employing a linear mixed-effects model adjusted for baseline Motherisk–pregnancy-unique quantification of nausea and emesis scores, which served as the primary endpoint. Secondary outcomes included Motherisk–pregnancy-unique quantification of nausea and emesis nausea and vomit and retch subscores, oral nutrition, global satisfaction of treatment, relief, desire to continue therapy, Nausea and Vomiting of Pregnancy Quality of Life, and Hyperemesis Gravidarum Pregnancy Termination Consideration. Adjustments for multiple comparisons were made employing the false discovery rate.A total of 31 patients with hyperemesis gravidarum were enrolled from October 2014 to May 2019. Among the 21 patients providing primary outcome data (12 assigned to gabapentin and 9 to the active comparator arm), 18 were enrolled as outpatients and all 21 were outpatients from days 5 to 7. The study groups’ baseline characteristics were well matched. Gabapentin treatment provided a 52% greater reduction in days 5 to 7 baseline adjusted Motherisk–pregnancy-unique quantification of nausea and emesis total scores than treatment with active comparator (95% confidence interval, 16–88; P=.01). Most secondary outcomes also favored gabapentin over active comparator treatment including 46% and 49% decreases in baseline adjusted Motherisk–pregnancy-unique quantification of nausea and emesis nausea (95% confidence interval, 19–72; P=.005) and vomit and retch subscores (95% confidence interval, 21–77; P=.005), respectively; a 96% increase in baseline adjusted oral nutrition scores (95% confidence interval, 27–165; P=.01); and a 254% difference in global satisfaction of treatment (95% confidence interval, 48–459; P=.03). Relief (P=.06) and desire to continue therapy (P=.06) both showed trends favoring gabapentin treatment but Nausea and Vomiting of Pregnancy Quality of Life (P=.68) and Hyperemesis Gravidarum Pregnancy Termination Consideration (P=.58) did not. Adverse events were roughly equivalent between the groups. There were no serious adverse events.In this small trial, gabapentin was more effective than standard-of-care therapy for reducing nausea and vomiting and increasing oral nutrition and global satisfaction in outpatients with hyperemesis gravidarum. These data build on previous findings in other patient populations supporting gabapentin as a novel antinausea and antiemetic therapy and support further research on gabapentin for this challenging complication of pregnancy." @default.
• W2101178715 created "2016-06-24" @default.
• W2101178715 creator A5011199572 @default.
• W2101178715 creator A5061350734 @default.
• W2101178715 creator A5084709068 @default.
• W2101178715 creator A5089843747 @default.
• W2101178715 date "2010-01-01" @default.
• W2101178715 modified "2023-10-16" @default.
• W2101178715 title "Reply to 'Cord clamp insult may predispose to SIDS'" @default.
• W2101178715 cites W2053311223 @default.
• W2101178715 cites W2094978429 @default.
• W2101178715 cites W2127164579 @default.
• W2101178715 cites W2148070200 @default.
• W2101178715 doi "https://doi.org/10.1016/j.earlhumdev.2009.12.002" @default.
• W2101178715 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20071109" @default.
• W2101178715 hasPublicationYear "2010" @default.
• W2101178715 type Work @default.
• W2101178715 sameAs 2101178715 @default.
• W2101178715 citedByCount "2" @default.
• W2101178715 countsByYear W21011787152012 @default.
• W2101178715 countsByYear W21011787152022 @default.
• W2101178715 crossrefType "journal-article" @default.
• W2101178715 hasAuthorship W2101178715A5011199572 @default.
• W2101178715 hasAuthorship W2101178715A5061350734 @default.
• W2101178715 hasAuthorship W2101178715A5084709068 @default.
• W2101178715 hasAuthorship W2101178715A5089843747 @default.
• W2101178715 hasConcept C126322002 @default.
• W2101178715 hasConcept C131872663 @default.
• W2101178715 hasConcept C142724271 @default.
• W2101178715 hasConcept C187212893 @default.
• W2101178715 hasConcept C197934379 @default.
• W2101178715 hasConcept C204787440 @default.
• W2101178715 hasConcept C2776608144 @default.
• W2101178715 hasConcept C2777170512 @default.
• W2101178715 hasConcept C2778409550 @default.
• W2101178715 hasConcept C2779234561 @default.
• W2101178715 hasConcept C2780580376 @default.
• W2101178715 hasConcept C2780852908 @default.
• W2101178715 hasConcept C2908647359 @default.
• W2101178715 hasConcept C42219234 @default.
• W2101178715 hasConcept C54355233 @default.
• W2101178715 hasConcept C71924100 @default.
• W2101178715 hasConcept C86803240 @default.
• W2101178715 hasConcept C99454951 @default.
• W2101178715 hasConceptScore W2101178715C126322002 @default.
• W2101178715 hasConceptScore W2101178715C131872663 @default.
• W2101178715 hasConceptScore W2101178715C142724271 @default.
• W2101178715 hasConceptScore W2101178715C187212893 @default.
• W2101178715 hasConceptScore W2101178715C197934379 @default.
• W2101178715 hasConceptScore W2101178715C204787440 @default.
• W2101178715 hasConceptScore W2101178715C2776608144 @default.
• W2101178715 hasConceptScore W2101178715C2777170512 @default.
• W2101178715 hasConceptScore W2101178715C2778409550 @default.
• W2101178715 hasConceptScore W2101178715C2779234561 @default.
• W2101178715 hasConceptScore W2101178715C2780580376 @default.
• W2101178715 hasConceptScore W2101178715C2780852908 @default.
• W2101178715 hasConceptScore W2101178715C2908647359 @default.
• W2101178715 hasConceptScore W2101178715C42219234 @default.
• W2101178715 hasConceptScore W2101178715C54355233 @default.
• W2101178715 hasConceptScore W2101178715C71924100 @default.
• W2101178715 hasConceptScore W2101178715C86803240 @default.
• W2101178715 hasConceptScore W2101178715C99454951 @default.
• W2101178715 hasIssue "1" @default.
• W2101178715 hasLocation W21011787151 @default.
• W2101178715 hasLocation W21011787152 @default.
• W2101178715 hasOpenAccess W2101178715 @default.
• W2101178715 hasPrimaryLocation W21011787151 @default.
• W2101178715 hasRelatedWork W2028082284 @default.
• W2101178715 hasRelatedWork W2038401300 @default.
• W2101178715 hasRelatedWork W2344374917 @default.
• W2101178715 hasRelatedWork W2610311809 @default.
• W2101178715 hasRelatedWork W2802226367 @default.
• W2101178715 hasRelatedWork W2830556954 @default.
• W2101178715 hasRelatedWork W2946639553 @default.
• W2101178715 hasRelatedWork W2954441274 @default.
• W2101178715 hasRelatedWork W4200197984 @default.
• W2101178715 hasRelatedWork W4254012728 @default.
• W2101178715 hasVolume "86" @default.
• W2101178715 isParatext "false" @default.
• W2101178715 isRetracted "false" @default.
• W2101178715 magId "2101178715" @default.
• W2101178715 workType "article" @default.